Stock comparison
Bio-Rad Laboratories
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIO
Bio-Rad Laboratories
Market cap
$7.78B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIO | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 75B | IDXX |
| Benjamin Graham | 48D | 80A | IDXX |
| Philip Fisher | 30F | 75B | IDXX |
| Peter Lynch | 10F | 71B | IDXX |
| Joel Greenblatt | 42D | 83C | IDXX |
| Charlie Munger | 34F | 87A | IDXX |
| Terry Smith | 26F | 84A | IDXX |
Side-by-side metrics
| Metric | BIO | IDXX |
|---|---|---|
| Market cap | $7.78B | $44.12B |
| P/E (TTM) | 39.5x | 39.0x |
| EV/EBIT | 28.0x | 31.6x |
| ROIC (TTM) | 1.95% | 40.66% |
| Gross margin | 51.87% | 62.05% |
| Net margin | 6.52% | 24.63% |
| Revenue CAGR 5y | -3.04% | 7.56% |
| EPS CAGR 5y | -33.51% | 10.79% |
| Debt / Equity | 0.2x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
- Debt / Equity0.2xvs 0.7x+71%
- EV/EBIT28.0xvs 31.6x+12%
IDXX leads on
- Revenue CAGR 5y7.56%vs -3.04%+140%
- EPS CAGR 5y10.79%vs -33.51%+132%
- ROIC (TTM)40.66%vs 1.95%+95%
- Market cap$44.12Bvs $7.78B+82%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.